EMBRYONIC DEVELOPMENT & STEM CELL COMPENDIUM
Content
All Cell Therapies > Cell Therapy Card
Sign in for full access

Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution

HPC (Hematopoietic Progenitor Cell) Cord Blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated-donor hematopoietic progenitor stem cell transplantation procedures. The therapy is delivered in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. Matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended. The incidence of classic grade III–IV graft vs host disease is 19%.

Clinical trial NCT00737516 which is common to several products. Contraindications: Known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40 or plasma proteins. Fatal infusion reactions: administration can result in serious, including fatal, infusion reactions. Graft-vs.-host disease (GVHD): GVHD is expected after administration, and may be fatal. Administration of immunosuppressive therapy may decrease the risk of GVHD. Engraftment syndrome: Engraftment syndrome may progress to multi-organ failure and death. Treat engraftment syndrome promptly with corticosteroids. Graft failure: Graft failure may be fatal.
See additional Cell Therapies for: Blood
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Home
Contact Us
About Terms of Use Privacy Policy
Copyright LifeMap Sciences, Inc. - All Rights Reserved (v4.14 Build 1)
This site does not provide medical advice and is for research use only